Association of Circulating GDF-15 with Fetal Growth in Gestational Diabetes

<b>Background/Objectives</b>: Growth differentiation factor-15 (GDF-15) is a component of the transforming growth factor beta (TGF-β) family that may act as regulator of inflammation. A possible protective role of GDF-15 against glucose alterations has been hypothesized. The aim of this pilot study was to evaluate the relationship between a circulating concentration of GDF-15 and metabolic/inflammatory parameters, as well as with adverse perinatal outcomes in patients with gestational diabetes mellitus (GDM). <b>Methods</b>: Twenty-four (<i>n</i> = 24) patients with GDM and <i>n</i> = 29 age-matched pregnant women with normal glucose tolerance (NGT) were recruited at the third trimester of gestation. Clinical and biochemical parameters were collected. Serum levels of GDF-15, small dense low density lipoprotein cholesterol (sdLDL), interleukin 6 (IL-6), a Soluble Urokinase Plasminogen Activator Receptor (su-PAR) were measured by an enzyme-linked immunosorbent assay kit. Fetal ultrasound parameters, maternal, delivery, and perinatal outcomes, were assessed. <b>Results:</b> Serum GDF-15 did not differ between GDM and NGT (<i>p</i> = 0.286). However, in linear regression analysis, a significant negative association was observed between GDF-15 and fetal weight percentile at the third trimester, only in patients with GDM (<i>p</i> = 0.013), even after adjustment for age and pre-pregnancy BMI (<i>p</i> = 0.029). GDF-15 positively associated with IL-6, adjusting for pre-pregnancy BMI (<i>p</i> = 0.047). Pregnant women with adverse perinatal outcomes had higher levels of GDF-15 (<i>p</i> = 0.043). In the regression model, higher levels of GDF-15 were associated with an increased likelihood of adverse perinatal outcomes after adjustment for age and pre-pregnancy BMI (<i>p</i> = 0.044). <b>Conclusions</b>: Besides its action as regulator of inflammation, GDF-15 might have a possible protective role against hyperglycemia-related excessive fetal growth in GDM. GDF-15 circulating levels might also be related to adverse perinatal outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-04-17
DOI
https://doi.org/10.3390/jcm14082764
Citations
3
Primary Topic
GDF15 and Related Biomarkers
Type
article
Field-Weighted Citation Impact
5.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of Circulating GDF-15 with Fetal Growth in Gestational Diabetes

Valentina Viggiani, Massimiliano Caprio, Susanna Morano, Stefania Gorini et al.
3 citations
Journal of Clinical Medicine
GDF15 and Related Biomarkers
5.00
article

Association of Circulating GDF-15 with Fetal Growth in Gestational Diabetes

Valentina Viggiani, Massimiliano Caprio, Susanna Morano, Stefania Gorini, Tiziana Filardi, Antonio Angeloni, Giuseppe Rizzo, Emanuela Anastasi, Enrico Bleve, Paola Galoppi
article en
3 citations

Abstract

<b>Background/Objectives</b>: Growth differentiation factor-15 (GDF-15) is a component of the transforming growth factor beta (TGF-β) family that may act as regulator of inflammation. A possible protective role of GDF-15 against glucose alterations has been hypothesized. The aim of this pilot study was to evaluate the relationship between a circulating concentration of GDF-15 and metabolic/inflammatory parameters, as well as with adverse perinatal outcomes in patients with gestational diabetes mellitus (GDM). <b>Methods</b>: Twenty-four (<i>n</i> = 24) patients with GDM and <i>n</i> = 29 age-matched pregnant women with normal glucose tolerance (NGT) were recruited at the third trimester of gestation. Clinical and biochemical parameters were collected. Serum levels of GDF-15, small dense low density lipoprotein cholesterol (sdLDL), interleukin 6 (IL-6), a Soluble Urokinase Plasminogen Activator Receptor (su-PAR) were measured by an enzyme-linked immunosorbent assay kit. Fetal ultrasound parameters, maternal, delivery, and perinatal outcomes, were assessed. <b>Results:</b> Serum GDF-15 did not differ between GDM and NGT (<i>p</i> = 0.286). However, in linear regression analysis, a significant negative association was observed between GDF-15 and fetal weight percentile at the third trimester, only in patients with GDM (<i>p</i> = 0.013), even after adjustment for age and pre-pregnancy BMI (<i>p</i> = 0.029). GDF-15 positively associated with IL-6, adjusting for pre-pregnancy BMI (<i>p</i> = 0.047). Pregnant women with adverse perinatal outcomes had higher levels of GDF-15 (<i>p</i> = 0.043). In the regression model, higher levels of GDF-15 were associated with an increased likelihood of adverse perinatal outcomes after adjustment for age and pre-pregnancy BMI (<i>p</i> = 0.044). <b>Conclusions</b>: Besides its action as regulator of inflammation, GDF-15 might have a possible protective role against hyperglycemia-related excessive fetal growth in GDM. GDF-15 circulating levels might also be related to adverse perinatal outcomes.

Journal of Clinical MedicineVol. 14(8)
Vita-Salute San Raffaele University (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), Sapienza University of Rome (IT)
Good health and well-being
Openalex Percentile: Top 5%
GDF15 and Related Biomarkers
5.00
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.